natgillin/translations-raw huggingface dataset:
purifying said recombinant protein to a filtered bulk for storage (FBS), wherein said filtered bulk does not contain detectable 1,4-dihydroxy-2-naphthoate (DHNA)-recombinant protein adduct, as measured by an ion exchange chromatography (IEC) assay at 310 nm. 
(c) pročišćavanje spomenutog rekombinantnog proteina u filtriranu rinfuzu za pohranu (FBS), pri čemu spomenuta filtrirana rinfuza ne sadrži detektabilni zbroj od 1,4-dihidroksi-2-naftoata (DHNA) i rekombinantnog proteina, izmjereno testom kromatografije ionske izmjene (IEC) pri 310 nm.
The engine (100) of claim 6, further comprising a fuel injection system operable to add fuel to an exit end of the passage (144). 
Motor (100) iz patentnog zahtjeva 5, naznačen time što dalje obuhvaća: sustav injiciranja goriva koji radi tako da dodaje gorivo u izlazni kraj zaobilazne cijevi (114).
ii) determining an inflection point of the net charge versus pH curve by determining a second derivative of the curves of step i); wherein an optimal ion exchange chromatography condition is a pH at a common inflection point for the two or more target polypeptides; 
gdje je optimalno stanje kromatografije ionske izmjene pH vrijednost pri zajedničkoj točki infleksije za dva ili više ciljnih polipeptida;
Lymphomas include, but are not limited to AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system. 
Uporaba dihidrokloridne soli prema zahtjevu 10, naznačena time da je navedeni limfom odabran od limfoma povezanog s AIDS-om, non-Hodgkinovog limfoma, limfoma kutanih T-stanica, Burkittovog limfoma, Hodgkinove bolesti, te limfoma središnjeg živčanog sustava.
an antibody which is capable of binding an epitope of human IAPP and proIAPP, wherein the antibody or the IAPP and proIAPP binding fragment thereof comprises in its variable region the following six CDRs: 
antitijelo koje je sposobno vezati epitop humanog IAPP i proIAPP, pri čemu antitijelo ili IAPP i njegov proIAPP vezujući fragment sadrže u svojoj varijabilnoj regiji slijedećih šest CDR:
After stirring the mixture at 57°C for 2 hours, the temperature was brought to 10°C over 6 hours. 
Nakon miješanja smjese na 57 "C tijekom 2 sata, temperatura je dovedena na 10 "C tijekom 6 sati.
The non-hygroscopic bulking agent may be present in the solid pharmaceutical dosage form in an amount from about 10% to about 90%, preferably from about 30% to about 70%, and more preferably from about 40% to about 60%, by weight of the total composition. A preferred embodiment of the present invention is set out in Table 1. 
Čvrsti dozirni oblik prema zahtjevima 4 do 6, naznačen time, da je nehigroskopno sredstvo za povećanje obujma prisutno u količini od oko 90 masenih % od ukupnog sastava, Čvrsti dozirni oblik prema zahtjevima 1 do 7, naznačen time, da doziri oblik ima sljedeći sastav: Komponente
The above liquid, once put into the vessel equipped with the appropriate device, supplied a soft and persisting foam, which could be spread on the nails providing a matte film that strongly adhered to the nail surface. 
Gore navedena tekućina, jednom kad je stavljena u posudu opremljenu s odgovarajućim uređajem, dala je mekanu i trajnu pjenu, koja se mogla razmazati po noktima, dajući matirani film koji je jako prijanjao na površinu nokta.
A composition according to claim 1, wherein an amount effective for amelioration of skin sagging, creasing and/or wrinkling is an amount which ameliorates skin sagging, creasing and/or wrinkling for at least about 8 hours, preferably for up to about 12 hours, more preferably for up to about 18 hours, and most preferably for up to about 24 hours. 
Spoj prema zahtjevu 1, naznačen time da je količina koja djelotvorno ublažava opuštanje, mreškanje i/ili boranje kože ona količina koja ublažava opuštanje, mreškanje i/ili boranje kože u trajanju od oko najmanje 8 sati, a poželjno je da to bude do oko 12 sati, još je poželjnije do oko 18 sati a najpoželjnije je da to bude do oko 24 sata.
3-Cyanomethylene-pyrrolidine-1-carboxylic acid ethyl ester The product was obtained by analogy with the method described in example 1 (step1.1) and using 3-oxo-pyrrolidine-1-carboxylic acid ethyl ester prepared according to Visconti, M et al. Helvetica Chimica Acta 1967, 50(5) 1289-93. 
Produkt se dobije postupkom analognim onom opisanom u primjeru | (korak 1.1), uz upotrebu etilnog estera 3- oksopirolidin-1-karboksilne kiseline, dobivenog prema M. Visconti 1 dr.: Helvetica Chimica Acta, 50(5), 1289-93, 6.2 Ctl-3-amino-3-(cijanometil)pirolidin-1-karboksilat
The system of any preceding claim, wherein propelling means (4) comprises a rail system, a cable system, a self-propelled system, a manually propelled system, a robotic system, a system guided from a distance, a boat with an engine, a floating device with an engine, or a combination thereof. 
Uređaj iz bilo kojeg od patentnih zahtjeva 7 do 9, pri čemu klizno sredstvo (4) obuhvaća sustav tračnica, sustav kablova, samopomični sustav, robotski sustav, sustav navođen iz daljine, brod s motorom, plutajuću napravu s motorom, ili njihovu kombinaciju.
iv) cycloalkyl optionally substituted with alkyl optionally substituted with one to three halogens; 
iv) cikloalkil, izborno supstituiran s alkilom, izborno supstituiranim s jednim do tri halogena;
An antibody or antigen binding portion thereof of any one of claims 1 to 7 or a composition of claim 8 for use according to claim 11, wherein: the second antibody is an anti-IGF1R antibody, an anti-EGFR antibody, or an anti-cmet antibody; or 
Protutijelo ili njegov dio za vezanje na antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 8 za uporabu u skladu s patentnim zahtjevom 20, naznačeno time, da je protutijelo protiv karcinoma protu-IGF1R protutijelo, protu-EGFR protutijelo ili protu-cMet protutijelo.
0.5 Total weight (for 530,000 lozenges) 
0.5 Ukupna masa (za 530,000 tableta)
A pharmaceutical composition comprising 4-chloro-3-ethyl-1-methyl- N -[[4-(4-methylphenoxyl)phenyl]methyl]-1H-pyrazole-5-carboxamide or a salt thereof for use in the topical treatment of a non-human mammal infested with an ectoparasite, wherein the ectoparasite is selected from Boophiliis spp, Rhipicephalus spp, Dermacentor spp, Hyalomma spp, Amblyomma spp, Otobius spp, Ornithodoros spp, Damalinia spp, Bovicola spp or Ctenocephalides spp, and wherein the non-human mammal is selected from livestock and domestic mammals. 
HR P20180887 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak, pri čemu se pripravak sastoji od 5-kloro-N-[2-[4-(2-etoksietil)-2,3-dimetillfenoksiletil]-6-etil-4-pirimidinamina ili njegove soli kao aktivnog spoja u jediničnom obliku doziranja, naznačen time da je namijenjen upotrebi za liječenje sisavca koji nije čovjek zaraženog ektoparazitom, pri čemu je ektoparazit odabran od Boophiliis spp, Rhipicephalus spp, Dermacentor spp, Hyalomma spp, Amblyomma spp, Otobius spp, Ornithodoros spp, Damalinia spp, Stomoxys spp, Bovicola spp, reda Diptera ili Ctenocephalides spp, te pri čemu je sisavac koji nije čovjek odabran od stoke i domaćih sisavaca.
A container according to any of the preceding claims, further comprising an inner frame within the inner package. 
Spremnik (600) prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da nadalje sadrži unutrašnji okvir unutar unutrašnjeg pakiranja (606).
V is hydrogen, straight- or branched-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, which one or more methylenes is optionally interrupted or terminated by O, S, S(O), SO2, N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; substituted or unsubstituted cycloalkyl; where R8 is hydrogen, acyl, aliphatic or substituted aliphatic; 
V je vodik, ravni- ili razgranati-, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani alkenil, supstituirani ili nesupstituirani alkinil, gdjejedan ili više metilena mogu biti prekinuti ili završeni sa O, S, S(O), SO2, N(R8), C(O), supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani heteroaril, supstituirani ili nesupstituirani heterocikal; supstituirani ili nesupstituirani cikloalkil; pri čemu R8 je vodik, acil, alifatski ili alifatski supstituirani.
Data was analyzed using Excel and PrismGraph. 
Podaci su analizirani uporabom Excel and PrismGraph.
A pharmaceutical composition comprising (i) a compound of the formula (1) and (ii) a cyclodextrin, wherein: 
Farmaceutska kompozicija koja sadrži spoj sa formulom (2): i ciklodekstrin.
Controlled release pharmaceutical compositions comprising a fumaric acid ester 
FARMACEUTSKI SASTAV ZA KONTROLIRANO OTPUŠTANJE KOJI SADRŽI ESTER FUMARNE KISELINE
The method of claim 8, wherein the enantiomeric excess of said compound is at least about 80%. 
Spoj prema zahtjevu 6, naznačen time, da enantiomerni višak navedenog spoja iznosi najmanje oko 80%.
A maleate salt of compound (I) represented by the following structural formula: 
Maleat sol spoja (I) je predstavljena slijedećom strukturnom formulom:
angiotensin converting enzyme (ACE) Inhibit or a pharmaceutically acceptable salt thereof, 
(ili) inhibitor angiotenzina koji pretvara enzime (ACE) ili njegova farmaceutski prihvatljiva sol,
The method according to claim 1, wherein the data concerning both particular blood type and the bags containing it are used to generate a signal of lack of bags and/or to identify a minimum supply of bags containing blood of said blood type. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, kod kojega se podaci koji se odnose na naročitu krvnu grupu i na vrećice koje sadržavaju tu krv koriste za generiranje signala manjka vrećica i/ili za identificiranje minimuma snabdjevenosti s vrećicama koje sadržavaju krv navedene krvne grupe.
A compound as claimed in claim 1 or 2 for use in the treatment or prevention of a central nervous system disorder, inflammation, pain, or neovascularization. 
Spoj prema zahtjevu 1 ili 2 za upotrebu u liječenju ili prevenciji poremećaja središnjeg živčanog sustava, upale, boli ili neovaskularizacije.
The scooter according to claim 1, wherein the transmission includes two endless transmission elements, which are arranged in series and each connect transmission wheels of different diameters. 
Skuter prema jednom od prethodnih zahtjeva, gdje prijenos (6) obuhvaća dva beskrajna elementa prijenosa, kao što je remen ili lanac, koji se nalaze u seriji i svaki povezuje prijenosna kola različitih promjera.
The transmitting method according to claim 5, wherein the remaining bits are MSBs Most Significant Bits, of the resource allocation information and the specified value is zero. 
Postupak prijenosa prema zahtjevu 9 ili 10, naznačen time da su preostali bit(ovi) MSB-i, NajBitniji Bitovi, podatka o dodjeli resursa, a definirana vrijednost je nula.
The method according to claim 1, wherein a packet continuity counter function is disabled in said modulators. 
Metoda prema jednom ili više od patentnih zahtjeva 1 do 5, gdje funkcija brojača kontinuiteta paketa je onemogućena u navedenim modulatorima (5,6).
The process according to any one of claims 1 to 6, wherein the carboxylic groups of the at least one carboxymethylcellulose are at least partly neutralized by adding to the aqueous mineral pigment material suspension prior or during the grinding step d) one or more polyvalent cations, in situ formed, by adding an acid, preferably H3PO4, or acidic reacting salt such as Na2HPO4, preferably CaHPO4. 
Postupak prema bilo kojem od zahtjeva 1 do 6, gdje su karboksilne skupine barem jedne karboksimetilceluloze barem djelomično neutralizirane tako da se vodenoj suspenziji mineralnog pigmentnog materijala dodaje prije ili za vrijeme koraka usitnjavanja d) jedan ili više polivalentnih kationa, in situ formiranih, putem dodavanja kiseline, poželjno H3POx, ili kiselo Teaktivne soli kao što je Na»HPOx, poželjno CaHPO1.
Assembly according to Claim 3, wherein the replaceable container contains liquid CO2. 
Sklop u skladu sa zahtjevom 3, naznačen time da zamjenjivi spremnik sadrži tekući CO».
The organic portion is washed with water (2×60 ml), dried (Na2SO4) and concentrated in vacuo to yield the titled compound as orange crystals. 
Organski dio se ispere s vodom (2 x 60 ml), osuši se (Na2SOx4) i koncentrira u vakuumu, čime se dobije naslovni spoj kao narančasti kristali.
The tablet of claim 1, wherein the content of the microcrystalline cellulose of (A) and the microcrystalline cellulose of (B) in the tablet is 5-40 wt % and 2-20 wt %, respectively. 
Tableta prema zahtjevu 1, naznačena time, da sadržaj mikrokristalične celuloze kod (A) i mikrokristalične celuloze kod (B) u tableti, iznosi od 5 do 40 masenih % odnosno od 2 do 20 masenih %.
Use of a polymorph according to any one of claims 1 to 12 in the manufacture of a medicament for the treatment or prophylaxis of anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, cognitive memory disorders, Parkinsons Disease, ADHD, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, stroke and also disorders associated with spinal trauma and/or head injury, IBS or obesity. 
Upotreba polimorfa prema bilo kojem od patentnih zahtjeva 1 do 12 u poroizvodnji lijeka za liječenje ili profilaksu anksioznosti, depresije, epilepsije, opsesivno-kompulzivnih poremećaja, migrene, poremećaja kognitivnog pamćenja, Parkinsonove bolesti, ADHD, poremećaja spavanja, poremećaja hranjenja, poput anoreksije i bulimije, napadaja panike, ustezanja od zloupotrebe narkotika, poput kokaina, etanola, nikotina i benzodiazepina, shizofrenije, inzulta, a također i poremećaja povezanih s ozljedama kralježnice i(li) glave, IBS ili pretilosti.
is hydrogen, C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C1-6 alkyl) or an optionally substituted C-amido; is hydrogen or C1-6 alkyl; 
je vodik, C1-6 alkil, po izboru supstituiran C3-6 cikloalkil, po izboru supstituiran aril, po izboru supstituiran aril(C1-6 alkil) ili po izboru supstituiran C-amido; je vodik ili C1-6 alkil;
The antibody or antigen-binding fragment thereof of claim 2, wherein the antibody or antigen-binding fragment comprises SEQ ID NO: 168 and SEQ ID NO: 282. 
antitijela ili antigen vezujućeg fragmenta istog koji sadržava VH i VL, pri čemu VH sadržava SEQ ID NO:170 a VL sadržava SEQ ID NO:283.
is chloro, fluoro, methoxy, or methyl; or a pharmaceutically acceptable C 1-6 ester, C 1-6 amide, or di (C 1-6 alkyl)amide or salt thereof. 
Rje klor; R* je klor, fluor, metoksi ili metil; ili farmaceutski prihvatljiv C 1.4 6ster, C,.g amid, ili di (C 1-6 alkiljamid ili njegova sol,
A compound according to claim 5, where Z is CO2Q, Q is hydrogen, and m is 4. 
Tvar u skladu s patentnim zahtjevom 5, pri čemu je Z jednak CO2Q, Q je vodik, a mje 4.
preparing a compound of formula VIII according to any one of claims 1 to 10 wherein PLG is the protecting-leaving group as set forth in claim 1, and Z is hydroxyethyl or the group convertible to hydroxyethyl as set forth in claim 1, reacting a compound of formula VIII with a compound of formula IX 
(i) < pripravljanje spoja formule VIII u skladu s bilo kojim od zahtjeva 1 do 10 gdje je PLG zaštitno-izlazna skupina kao što je izneseno u zahtjevu 1, a Z je hidroksietil ili skupina koja se može pretvarati u hidroksietil kao što je definirano u zahtjevu 1, (ii) reakcija spoja formule VIII sa spojem formule IX
CycQ; and provided that 
(7) CycQ; i uz uvjet da
1-1962 or a combination of lactic acid bacterium, Lactococcus lactis subsp. 
1-1962 ili kombinacija bakterije mliječnokiselog vrenja, Lactococcus lactis subsp.
223Ra as claimed in claim 3 wherein at least 99.9% of the 227Ac and/or at least 98% of the 227Th loaded onto the resin in step ii) is recovered in step x). 
Metoda u skladu s patentnim zahtjevom 2 ili s patentnim zahtjevom 3 pri čemu je najmanje 98% 227Th nanesenog na smolu u koraku ii) obnovljeno u koraku x).
The process according to claim 9, wherein the chiral phosphine ligand D is selected from a compound of formula (D1) to (D12): wherein: 
Postupak u skladu s patentnim zahtjevom 9, naznačen time, da je kiralni fosfinski ligand D odabran od spoja s formulama od (D1) do (D12):
The drag head according to claim 1, wherein the suction section is rotatable with respect to the heel section about an axis of rotation which is, in use, substantially horizontal and perpendicular to the dragging direction. 
Usisna glava (100) sukladno zahtjevu 1, pri čemu je usisni odjeljak (110) rotatabilan u odnosu na stražnji odjeljak (111) oko rotacijske osi koja je u uporabi horizontalna i okomita na smjer povlačenja.
A conjugate according to claims 12 to 14 wherein the cell binding agent is chosen from monoclonal antibodies; single chain antibodies; Fab, Fab', F(ab')2 and Fv, interferons; peptides; IL-2, IL-3, IL-4, IL-6; insulin, TRH (thyrotropin releasing hormones), MSH (melanocyte-stimulating hormone), steroid hormones, androgens, estrogens; EGF, TGFa, insulin like growth factor (IGF-I, IGF-II) G-CSF, M-CSF, GM-CSF; folate, transferrin. A pharmaceutical composition comprising a conjugate as defined in claims 12 to 15 or a compound as defined in claims 1 to 11 together with a pharmaceutically acceptable carrier. 
Konjugat u skladu s patentnim zahtjevom 3 do 8, naznačen time što se navedeno sredstvo za vezanje na stanicu bira između monoklonskih protutijela; kimernih protutijela; humaniziranih protutijela; posve ljudskih protutijela; jednolančanih protutijela; fragmenata protutijela, poput Fab, Fab', F(ab'), i Fv, interferona; peptida; limfokina, poput 1IL-2, IL-3, IL-4, IL-6; hormona, poput inzulina, TRH (tireooslobađajućih hormona), MSH (melanostimulirajućeg hormona), steroidnih hormona, poput androgena i estrogena; čimbenika rasta i čimbenika stimulacije kolonija, poput EGF, TGFa, inzulinu sličnog čimbenika rasta (IGF-L, IGF-Il) G-CSF, M-CSF i GM- CSF; vitamina, poput folata i transferina.
The multi-armed polymer prodrug of embodiment 31, having the structure: where n ranges from 40 to 500. 
PATENTNI ZAHTJEVI x Višestruko razgranati polimerni prolijek koji ima strukturu: gdje je n u rasponu od 40 do 500.
is an C1alkylaryl optionally substituted by one or more substituents independently selected from the group consisting of halogen, aryloxy, aryl, alkylamino, dialkylamino, C1-6 alkyl, —CO2H, —CO2C1-6 alkyl, —CO2NH2,—SO2NH2, —CN and C1-6 alkoxy; and 
ili pri čemu je alkilaril proizvoljno supstituiran s jednim ili više supstituenata koji se neovisno biraju iz niza koji sadrži halogen, ariloksi, aril, alkilamino, dialkilamino, C1-6 alkil, karboksilnu kiselinu, karboksilni ester, karboksilni amid, sulfonamid, nitril, ili C1-6 alkoksi;
Consistent with a proposed mechanism of action in which DHFR is the main target, the addition of thymidine reversed cytotoxicity induced by the compounds of formula I only at high concentrations. 
U skladu s predloženim mehanizmom djelovanja u kojem je DHFR glavna meta, dodatak timidina promijenio je citotoksičnost induciranu spojevima formule I samo pri visokim koncentracijama.
contacting the antigen presenting cell of step (iii) with a T cell to evaluate the ability of the peptide to simulate the T cell; and 
stavljanja u kontakt predočnih stanica iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da stimulira T-stanice; i
for the manufacture of a medicament for treating cancer wherein said cancer is selected from the group consisting of: melanoma, pancreatic cancer, thryroid cancer, colorectal cancer, lung cancer, breast cancer, and ovarian cancer; or 
za proizvodnju lijeka za liječenje kancera, pri čemu je navedeni kancer izabran iz grupe koju čine: melanom, kancer pankreasa, kancer štitnjače kolorektalni kancer, kancer pluća, kancer dojke i kancer jajnika; ili
Granulating or agglomerating the sugar replacer offers further advantages and added value to the product, such as: 
Granulacijom ili aglomeracijom, zamjena za šećer osigurava nove prednosti proizvodu i povećava mu vrijednost.
According to the example of WO 95/01471, the silicon containing polymer is prepared by polycondensation of the monomers dimethyl terephthalate and ethylene glycol with an addition of 3.9% by weight of polydimethyl siloxane and manganese acetate. An antimony catalyst is used as an essential component of said polycondensation process. 
Prema primjeru WO 95/01471, polimer koji sadrži silikon pripravi se polikondenzacijom monomera dimetil tereftalata 1 etilen glikola uz dodatak polidimetil siloksana i manganova acetata u količini od 3.9 % težine, uz uporabu antimonskog katalizatora kao nužne komponente navedenog polikondenzacijskog procesa.
wherein said stabilizing agent is sucrose at a concentration of about 1.5% to about 20% w/v; 
navedeno sredstvo za dopunjavanje je 4.0 % w/v manitol; i navedeni stabilizator je 2.0 % w/v saharoza;
S(OAlk) meaning a serine, the hydroxyl group of which is substituted by a linear or branched alkanoyl group having from 1 to 20 carbon atoms, 
S(O-alkanoil) predstavlja serin, čija je hidroksilna skupina supstituirana s ravnom ili razgranatom alkanoil skupinom koja ima od 1 do 20 ugljikovih atoma,
applying to the hair a second formulation comprising a binding agent of Formula I wherein 
(b) nanošenje na kosu druge formulacije koja sadrži sredstvo za vezanje formule I
50-85 wt.% of a highly unsaturated oil selected from the group consisting of sunflower oil, soybean oil, rapeseed oil, cottonseed oil, safflower oil, marine oil, corn oil, olive oil, linseed oil and combinations thereof; and 
- 50-85 %, težinski, visoko nezasićenog ulja, koje se bira iz skupine koju čine suncokretovo ulje, sojino ulje, ulje od uljane repice, ulje od pamukovog sjemena, ulje šafranike, riblje ulje, kukuruzno ulje, maslinovo ulje, laneno ulje i njihovih kombinacija; i
The pharmaceutical composition according to claim 1 or 2, wherein the composition provides steady state plasma levels of 3 a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1 ili 2, naznačen time da daje stacionarno stanje razine u plazmi 30a-hidroksi-3-metoksimetil-2 1-(1*-imidazolil)-5a-pregnan-20-ona u rasponu od 50 ng/ml to 250 ng/ml.
The compound of any of claims 1 or 2, wherein Ar1 and/or Ar2 are selected from phenyl, pyridyl, pyrimidyl, imidazolyl, pyrazolyl, thiophenyl, triazolyl, in particular from phenyl, 3-pyridyl, 5-pyrimidyl, 2-imidazolyl, 3-pyrazolyl, 2-thiophenyl, 5-triazolyl. 
Farmaceutska kompozicija iz patentnog zahtjeva 1, gdje Ar1 i/ili Ar2 su odabrani od fenil, piridil, pirimidil, imidazolil, pirazolil, tiofenil, triazolil.
The subject is preferably a mammalian subject, such as a human subject or patient. Such conditions may include, for example, HIV infection, various degenerative diseases, such as neurodegenerative disease, degenerative disease of the bones or joints, macular degeneration, atherosclerosis, and anemia. Such conditions also include wounds or other acute or chronic conditions of the epidermis, such as, for example, a burn, an abrasion, an incision, a graft site, a lesion caused by an infectious agent, a chronic venous ulcer, a diabetic ulcer, a compression ulcer, a pressure sores, a mucosal ulcer, and keloid formation. 
R* tvori, zajedno s ugljikom 9, kondenzirani ciklopropilni prsten, a predstavlja jednostruku vezu između ugljika 9 i 11, naznačena time što je spoj u količini djelotvornoj u upotrebi u liječenju Alzheimerove bolesti, Parkinsonove bolesti, Huntingtonove bolesti, makularne degeneracije, anemije ili kroničnog ili akutnog stanja epidermisa kojeg se bira iz skupine koju čine rana, opeklina, abrazija, incizija, mjesto presatka, lezija uzrokovana uzročnikom zaraze, kronični venski ulkus, dijabetični ulkus, kompresijski ulkus, dekubitus, mucosal sore ili ulkusna i keloidna formacija, povećavanjem aktivnosti telomeraze u pacijentovim stanicama ili tkivu.